Free Trial
NASDAQ:LIPO

Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

Lipella Pharmaceuticals logo
$2.63 +0.21 (+8.68%)
(As of 11/22/2024 ET)

About Lipella Pharmaceuticals Stock (NASDAQ:LIPO)

Key Stats

Today's Range
$2.42
$2.70
50-Day Range
$2.31
$4.06
52-Week Range
$2.21
$12.00
Volume
81,845 shs
Average Volume
135,701 shs
Market Capitalization
$3.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Buy

Company Overview

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
61st Percentile Overall Score

LIPO MarketRank™: 

Lipella Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lipella Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lipella Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Lipella Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lipella Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lipella Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lipella Pharmaceuticals has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.23% of the float of Lipella Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lipella Pharmaceuticals has recently decreased by 98.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lipella Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Lipella Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the float of Lipella Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lipella Pharmaceuticals has recently decreased by 98.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lipella Pharmaceuticals has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lipella Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lipella Pharmaceuticals' insider trading history.
Receive LIPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LIPO Stock News Headlines

Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)
A “Thank You Gift” From Pres. Trump - Genius
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Lipella issued patent by USPTO for liposomal drug delivery platform
See More Headlines

LIPO Stock Analysis - Frequently Asked Questions

Lipella Pharmaceuticals' stock was trading at $8.16 at the start of the year. Since then, LIPO shares have decreased by 67.8% and is now trading at $2.63.
View the best growth stocks for 2024 here
.

Lipella Pharmaceuticals's stock reverse split on the morning of Friday, November 8th 2024. The 1-8 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share.

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), MSP Recovery (LIFW), NVIDIA (NVDA), Processa Pharmaceuticals (PCSA), Energy Transfer (ET) and Labor Smart (LTNC).

Company Calendar

Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIPO
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+508.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,620,000.00
Net Margins
-882.82%
Pretax Margin
-882.61%

Debt

Sales & Book Value

Annual Sales
$450,000.00
Book Value
$1.21 per share

Miscellaneous

Free Float
821,000
Market Cap
$3.18 million
Optionable
Not Optionable
Beta
0.31
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:LIPO) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners